#1 Clinical Trials Search in Europe

Orismilast

Orismilast, a next-generation phosphodiesterase-4 (PDE4) inhibitor, is currently being studied in clinical trials for various inflammatory skin conditions. This article explores the ongoing research on Orismilast’s potential effectiveness and safety in treating hidradenitis suppurativa, psoriasis, and atopic dermatitis. We’ll delve into the key aspects of these trials and what they mean for patients suffering from these challenging skin disorders.

Table of Contents

What is Orismilast?

Orismilast is a new medication being developed to treat various inflammatory skin conditions[1]. It’s also known by other names such as UNI50001, LEO32731, and IBI353[3][2]. This drug is currently undergoing clinical trials to evaluate its effectiveness and safety in treating several skin disorders.

How Does Orismilast Work?

Orismilast is described as a “next generation PDE4 inhibitor”[3]. To understand this, let’s break it down:

  • PDE4: This stands for phosphodiesterase-4, which is an enzyme in our body that plays a role in inflammation.
  • Inhibitor: This means the drug works by blocking or reducing the activity of PDE4.
  • Next generation: This suggests that Orismilast is an improved version of existing PDE4 inhibitors.

By inhibiting PDE4, Orismilast aims to reduce inflammation in the body, particularly in the skin. It’s designed to have a high selectivity for specific PDE4 subtypes that are linked to inflammation, which may make it more effective or have fewer side effects than previous medications[3].

What Conditions Does Orismilast Treat?

Orismilast is being studied for several inflammatory skin conditions, including:

  • Hidradenitis Suppurativa (HS): A chronic skin condition that causes painful, inflamed lesions in areas where skin rubs together, such as the armpits or groin[1].
  • Psoriasis: A condition that causes rapid buildup of skin cells, resulting in scaly, itchy, and sometimes painful patches on the skin[3].
  • Atopic Dermatitis: Also known as eczema, this is a chronic condition that makes the skin red and itchy[4].

Current Clinical Trials

Orismilast is currently being tested in several clinical trials:

  • A study for treating mild to severe Hidradenitis Suppurativa in adults (OSIRIS study)[1].
  • A trial for moderate-to-severe plaque-type psoriasis in adults[3].
  • A study for moderate to severe atopic dermatitis in adults (ADESOS study)[4].
  • A safety and pharmacokinetic study in healthy Chinese adults[2].

These trials are designed to assess how well Orismilast works and how safe it is for patients with these conditions.

How is Orismilast Administered?

Orismilast is taken orally in the form of tablets. In the clinical trials, patients typically take the medication twice daily, once in the morning and once in the evening[3][4]. The dosage being tested ranges from 20 mg to 40 mg twice daily, depending on the specific trial and condition being treated.

How is Orismilast’s Effectiveness Measured?

The effectiveness of Orismilast is measured using various scales and assessments, depending on the condition being treated. Some common measures include:

  • For Hidradenitis Suppurativa: Changes in the count of abscesses and inflammatory nodules, and improvements in quality of life[1].
  • For Psoriasis: The Psoriasis Area and Severity Index (PASI) score, which measures the severity and extent of psoriasis[3].
  • For Atopic Dermatitis: The Eczema Area and Severity Index (EASI) score, which measures the extent and severity of eczema[4].

These measures help researchers determine how well the medication is working to reduce symptoms and improve patients’ quality of life.

Safety Considerations

As with any new medication, the safety of Orismilast is being carefully evaluated in these clinical trials. Researchers are monitoring for any side effects or adverse reactions that patients might experience. The trials include assessments of vital signs, laboratory examinations, physical examinations, and electrocardiograms (ECGs) to ensure patient safety[2].

It’s important to note that Orismilast is still in the testing phase and is not yet approved for general use. Patients interested in this treatment should discuss it with their healthcare provider and consider participating in clinical trials if appropriate.

Condition Study Phase Dosage Duration Primary Outcome
Hidradenitis Suppurativa Not specified 10 mg up to 40 mg, twice daily 16 weeks Percent change in abscess and nodule count
Psoriasis Phase 2b 20 mg, 30 mg, or 40 mg, twice daily 16 weeks Percent change in PASI score
Atopic Dermatitis Phase 2b 20 mg, 30 mg, or 40 mg, twice daily 16 weeks Percent change in EASI score
Healthy Subjects (Chinese) Phase 1 Not specified (multiple doses) 3 weeks Pharmacokinetic parameters

FAQ

  • What is Orismilast? Orismilast is a next-generation phosphodiesterase-4 (PDE4) inhibitor with demonstrated broad anti-inflammatory properties. It is being studied as a potential treatment for various inflammatory skin conditions.
  • What skin conditions is Orismilast being tested for? Orismilast is currently being tested in clinical trials for hidradenitis suppurativa, psoriasis, and atopic dermatitis. These are all chronic inflammatory skin conditions that can significantly impact a person's quality of life.
  • How is Orismilast administered? In the clinical trials, Orismilast is being administered as oral tablets. Patients typically take the medication twice daily, in the morning and evening, for a specified period (often 16 weeks in these studies).
  • What are the main outcomes being measured in these trials? The trials are primarily measuring the effectiveness of Orismilast by looking at changes in disease severity scores (such as PASI for psoriasis and EASI for atopic dermatitis), reduction in symptoms, and improvement in quality of life. They are also assessing the safety and tolerability of the drug.
  • When might Orismilast be available for patients? As Orismilast is still in clinical trials, it's not yet available for general use. The timeline for potential approval and availability will depend on the results of these studies and subsequent regulatory processes. It's important to note that not all drugs in clinical trials end up being approved for use.

Ongoing Clinical Trials on Orismilast

  • A study of orismilast alone or combined with semaglutide for weight management in people with obesity

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study of Orismilast for Treating Moderate to Severe Ulcerative Colitis in Adults

    Not recruiting

    2 1 1
    Investigated drugs:
    Denmark

Glossary

  • Phosphodiesterase-4 (PDE4) inhibitor: A type of drug that works by blocking an enzyme called phosphodiesterase-4, which is involved in inflammation. By inhibiting this enzyme, these drugs can reduce inflammation in various conditions.
  • Hidradenitis Suppurativa (HS): A chronic skin condition characterized by painful, inflamed lesions in areas where skin rubs together, such as the armpits, groin, and under the breasts.
  • Psoriasis: A chronic autoimmune condition that causes rapid buildup of skin cells, resulting in scaly, itchy, dry patches on the skin.
  • Atopic Dermatitis: A chronic, itchy skin condition also known as eczema. It's characterized by red, inflamed skin that can become cracked, blistered, and very itchy.
  • Psoriasis Activity and Severity Index (PASI): A tool used to measure the severity and extent of psoriasis. It takes into account the redness, thickness, and scaling of lesions, as well as the area of skin affected.
  • Eczema Area and Severity Index (EASI): A tool used to measure the extent and severity of atopic dermatitis (eczema). It assesses the affected area and intensity of symptoms.
  • Investigator Global Assessment (IGA): A scale used by healthcare professionals to assess the overall severity of a skin condition at a given point in time.
  • Quality of Life (QoL): A measure of an individual's well-being and ability to enjoy normal life activities, often used to assess the impact of a medical condition or treatment.
  • Placebo: An inactive substance or treatment used in clinical trials to compare the effects of a new drug. Participants receiving a placebo serve as a control group.
  • Modified Release: A drug formulation designed to release the active ingredient over time or at a specific time after administration, potentially improving effectiveness or reducing side effects.

References

  1. https://clinicaltrials.gov/study/NCT04982432
  2. https://clinicaltrials.gov/study/NCT05490316
  3. https://clinicaltrials.gov/study/NCT05190419
  4. https://clinicaltrials.gov/study/NCT05469464